Chemomab Therapeutics Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CMMB research report →
Price Chart
About the company
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24.
- CEO
- Adi Mor George
- IPO
- 2019
- Employees
- 12
- HQ
- Tel Aviv-Yafo, TA, IL
Get TickerSpark's AI analysis on CMMB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $9.58M
- P/E
- -0.88
- PEG
- -0.10
- P/S
- 0.00
- P/B
- 2.60
- EV/EBITDA
- -0.44
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -122.94%
- ROIC
- -302.73%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-9,567,000
- Net Income
- $-8,995,000+35.5%
- EPS
- $-1.42+97.9%
- OCF Growth
- +27.4%
- FCF Growth
- +27.4%
- 52W High
- $2.99
- 52W Low
- $0.92
- 50D MA
- $1.53
- 200D MA
- $1.73
- Beta
- 0.66
- RSI (14)
- 41
- Avg Volume
- 102.39K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Chemomab said CM-101 showed encouraging biomarker and FibroScan signals in NASH, while it advanced PSC and newly cleared SSc trials and extended cash runway to June 30, 2024.· May 11, 2023
- CM-101 Phase 2a NASH data showed safety and broad biomarker improvement, including almost 60% of treated patients improving in at least three biomarkers versus none on placebo.
- The PSC Phase 2 trial is enrolling across the US, Europe and Israel, with the company adding sites, a higher-dose cohort, and an open-label extension; top-line data are still targeted for the second half of 2024.
- The SSc Phase 2 trial was cleared by the FDA, is designed for 45 patients, and initial US site opening is expected around midyear.
- Cash, cash equivalents and bank deposits were $32.8 million at March 31, 2023, and management said runway has been extended to June 30, 2024.
- Management continues to explore partnership opportunities in NASH and other fibro-inflammatory indications, but said it is focused on PSC and SSc as lead programs.
For first quarter 2023, Chemomab reported net loss of $8.8 million, or approximately $0.04 per basic and diluted ordinary share, versus a net loss of $5.1 million, or approximately $0.02 per share, in the first quarter of 2022. Cash, cash equivalents and bank deposits were $32.8 million as of March 31, 2023, compared with approximately $40 million at December 31, 2022. R&D expenses were $6.9 million, up 151% from $2.7 million a year ago, while G&A expenses were $2.2 million, down 16% from $2.6 million. In the NASH Phase IIa study, 23 patients were enrolled and 8 doses of CM-101 were given subcutaneously at 5 mg/kg; management said the drug appeared safe, with mostly mild adverse events, one unrelated serious adverse event, no significant injection site reactions, and no evidence of anti-drug antibodies. Management said the cash runway has been extended from March 31, 2024 to June 30, 2024 through budget reductions, and it remains on track to report PSC double-blind top-line data in the second half of 2024 and initial SSc data in the second half of 2024.
Dale Pfost emphasized that the company is making progress on multiple fronts, highlighting the NASH data as supportive of CM-101’s broader fibro-inflammatory potential and especially relevant to PSC and SSc. He said Chemomab is not planning additional NASH studies on its own, but will continue to evaluate partnership opportunities there and in other indications. His tone was upbeat but disciplined, repeatedly stressing focus on the two lead programs and prudence with spending.
Don Marvin said the company is focused on the optimal development path for CM-101 while conserving capital, and reported that estimated cash runway has been extended to June 30, 2024 from March 31, 2024. He cited cash, cash equivalents and bank deposits of $32.8 million at March 31, 2023 versus about $40 million at December 31, 2022. He also detailed that R&D expense rose to $6.9 million from $2.7 million year over year due to increased clinical and preclinical activity, while G&A declined to $2.2 million from $2.6 million due mainly to lower share-based compensation and insurance expense.
Analysts asked about Chemomab’s conference plans and the timing of new data presentations; management said it plans to present at EASL Biliary, the broader EASL meeting in Vienna, and later potentially at US meetings such as EULAR and ACR, including data from clinical samples, preclinical work, and possibly NASH data if accepted as late-breaking. A question on partnering and NASH drew the response that discussions with companies include NASH, but Chemomab does not plan to run new NASH trials itself. On the SSc design, management explained that 10 mg/kg was selected to demonstrate tissue engagement in a Phase 2a setting, and that both limited and diffuse SSc were included because the diseases differ, both are severe, and management wants to explore CM-101 across patient groups including those with fewer dedicated therapeutic options.
The call reinforced that CM-101 has shown consistent safety and biomarker signals across multiple studies, including more than 70 healthy subjects and patients, which management says supports a fibro-inflammatory disease platform. The company also has multiple upcoming catalysts: PSC enrollment progress, a midyear SSc site start, scientific presentations, and top-line data from both PSC and SSc expected in the second half of 2024.
Chemomab remains a development-stage company with no commercial revenue and continued operating losses, and its cash runway only extends to June 30, 2024. Management also noted it is not planning additional NASH studies on its own, so any value there may depend on partners, while the PSC and SSc trials still need to deliver clinical proof of concept and readouts are months away.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 77.8%
- Shares Outstanding
- 8.05M
- Float Shares
- 6.26M
of shares held by institutions
13 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Citadel Advisors LLC | 109.76K | ▲ 14.45K |
| Kestra Private Wealth Services, LLC | 77.15K | ▲ 15.44K |
| Ikarian Capital, LLC | 51.79K | 0 |
| Rhumbline Advisers | 30.07K | ▼ 459 |
| Susquehanna International Group, Llp | 24.41K | ▲ 24.41K |
| Philadelphia Investment Partners, LLC | 22.57K | ▲ 7.57K |
| Jane Street Group, LLC | 19.64K | ▲ 19.64K |
| Stonex Group Inc. | 18.62K | ▲ 18.62K |
| Two Sigma Securities, LLC | 13.67K | ▲ 13.67K |
| Smartharvest Portfolios, LLC | 13.03K | ▲ 13.03K |
| Renaissance Technologies LLC | 10.33K | ▲ 10.33K |
| Bnp Paribas Financial Markets | 3.30K | ▼ 3.50K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 27, 26 | Cohen Neil Harris | sell | 1,304 |
| Aug 28, 26 | Cohen Neil Harris | sell | 1,000 |
| Mar 16, 26 | Cohen Neil Harris | other | 5,172 |
| Mar 16, 25 | Cohen Neil Harris | other | 3,821 |
| Mar 18, 24 | Cohen Neil Harris | other | 2,520 |
| Mar 21, 23 | Cohen Neil Harris | other | 1,714 |
| Mar 7, 22 | Cohen Neil Harris | other | 1,705 |
| Apr 19, 21 | Cohen Neil Harris | other | 2,971 |
| Jul 16, 20 | Cohen Neil Harris | other | 172 |
| Jun 1, 26 | Melincoff Gwen A | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CMMB coverage
Recent articles, reports, and earnings notes.
No research on CMMB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CMMB report →Chemomab Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · Nov 19
Chemomab Therapeutics and Scipher Medicine Announce SEC Registration Statement on Form S-4 Is Effective
globenewswire.com · Nov 2
Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference
globenewswire.com · Aug 31
Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · Aug 19
Chemomab Therapeutics Ltd. (CMMB) M&A Call Prepared Remarks Transcript
seekingalpha.com · Jul 8
Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis
globenewswire.com · Jul 8
Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · May 14
Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update
globenewswire.com · Mar 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.